Title: Is nocturnal desaturation a trigger for neuronal damage in chronic obstructive pulmonary disease?

Francois Alexandre^{1,2}, Nelly Heraud², Alain Varray¹

¹Movement To Health Laboratory, Euromov, University of Montpellier 1, Montpellier, France. ²Clinique du Souffle La Vallonie, Fontalvie, Lodève, France

Corresponding author:

Francois Alexandre, Movement To Health (M2H), Euromov, University of Montpellier 1, 700 avenue du Pic Saint Loup, 34090 Montpellier, France. Phone: (+33) 434 432 632; Fax: (+33) 434 432 644; E-mail: francois.alexandre@5-sante.fr

Summary

Patients with chronic obstructive pulmonary disease (COPD) present many neurological disorders of unknown origin. Although hypoxemia has long been thought to be responsible, several studies have shown evidence of neuronal damage and dysfunction even in non-hypoxemic patients with COPD. Adaptive mechanisms protect the brain from hypoxia: when arterial oxygen tension (PaO_2) decreases, the cerebral blood flow (CBF) increases, ensuring continuously adequate oxygen delivery to the brain. However, this mechanism is abolished during non-rapid eye movement (NREM) sleep. Any drop in PaO_2 during NREM sleep is therefore not compensated by increased CBF, causing decreased cerebral oxygen delivery with subsequent brain hypoxia. Patients with may therefore be exposed to neuronal damage during this critical time. This mechanism is of vital importance for patients with COPD because of the potentially deleterious cortical effects. Nocturnal desaturation is quite frequent in COPD and affects approximately one out of two patients who are not hypoxemic during wakefulness. Although the prevalence of NREM sleep desaturation has never been specifically assessed in COPD, current data suggest that at least half of the nocturnal desaturation in desaturating patients occurs during NREM sleep. This review presents the rationale for the hypothesis that nocturnal desaturation during NREM sleep promotes neuronal damage and dysfunction in COPD.

Introduction

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death worldwide. COPD is not restricted to the lung but instead has major systemic repercussions, and it is now considered to be a multi-component syndrome. Accordingly, the predictors of COPD survival include not only the degree of airflow obstruction, but also body mass index, dyspnea, exercise capacity, peripheral muscle size and strength, and the level of hypoxemia. Brain impairment is a well-documented secondary outcome of the disease, but surprisingly this is often forgotten (1). Yet recent reports have irrefutably confirmed severe anatomical brain impairment in COPD (2, 3) with significant functional repercussions that are not limited to cognitive disorders; for example, both peripheral muscle strength (4) and driving abilities (5) can be affected. The mechanisms of brain impairment are still not well understood, however, and it is therefore essential to determine their origins so that they can be better anticipated, with the ultimate goal being to prevent their deleterious effects. Although hypoxemia has long been thought to be responsible for brain impairment (6), several studies have shown evidence of neuronal damage and dysfunction even in non-hypoxemic patients with COPD (2, 7, 8). Adaptive mechanisms protect the brain from hypoxia: when arterial oxygen tension (PaO_2) decreases, the cerebral blood flow (CBF) increases, ensuring continuously adequate oxygen delivery to the brain (9-11). However, this mechanism is abolished during non-rapid eye movement (NREM) sleep (12-14). Therefore, any drop in PaO_2 during NREM sleep is not compensated by increased CBF, causing decreased cerebral oxygen delivery with subsequent brain hypoxia (15, 16).

Hypothesis

Given the high prevalence of nocturnal desaturation in patients with COPD (17-19) and the absence of cerebrovascular O₂ reactivity during NREM sleep stages (12-14), we hypothesize that nocturnal desaturation during NREM sleep may act as a trigger for neuronal damage and dysfunction in COPD (Figure 1).

Arguments to support the hypothesis

Anatomical brain impairment in COPD

Patients with COPD present many anatomical brain alterations. The neuronal damage in COPD was first characterized as periventricular white matter lesions (20) and cerebral metabolic abnormalities (21). Levels of N-acetyl aspartate, a marker of neuronal density, were also reported to be lower in patients with COPD compared with healthy controls (21). More recently, improvements in magnetic resonance imaging analyses through diffusion tensor imaging and voxel-based morphometry have provided better descriptions of the structural brain damage in COPD (2, 3, 22). Zhang et al. (22) found that gray matter volume was reduced bilaterally in the frontal cortex, the cingulate cortex and the left insular cortex in patients with COPD. They also identified gray matter deficits in many subcortical areas such as the right thalamus and left amygdala (22). Hippocampal atrophy was observed and associated with an increased level of serum S100b, a peripheral marker of glial cell impairment (23). In addition, a high prevalence of cerebral microbleeds and small cerebral vessel disease was found in patients with COPD (24), which is consistent with reports of both the decrease in microstructural integrity and the increase in white matter ultrastructural damage in several cortical and subcortical areas (2, 3).

Functional repercussions of brain impairment

The structural brain damage have several functional repercussions, although most studies have focused on cognitive dysfunction (see Dodd et al. (25) for review). The results of generic questionnaires such as the mini-mental state assessment (MMSE) or the Montreal cognitive assessment (MoCA) have shown globally impaired cognitive function in patients with COPD (23, 26). The P300 component of the event-related brain potential is a useful, objective clinical tool to assess cognitive function. Two studies reported longer P300 latency and lower P300 amplitude in patients with COPD compared with healthy controls, and both these measures are known to reflect attention deficits and impaired decision-making processes (7, 27). Another recent study found impairments in processing speed, working and episodic memory, and executive functions (2), with memory and attention capacities being most impaired (28). It should be noted that brain impairment is not systematic in COPD. Borson et al. (29) found no differences in hippocampal volume or white matter lesions between patients with COPD and healthy controls. Similarly, other studies have observed no significant differences in MMSE scores between patients with COPD and healthy controls (30). Recent studies have estimated the prevalence of cognitive dysfunction as being in the range of 27 to 36% (26, 31).

As noted above, the functional repercussions of neuronal damage are not restricted to cognitive functioning. For instance, driving ability may be severely impaired in patients with COPD (5, 32). Some studies have reported alterations in resting motor cortex excitability in these patients (33, 34), and another found a lower level of voluntary activation of the knee extensor muscles (35). In a recent study from our laboratory, we assessed the neural activity of the motor cortex during maximal voluntary contractions of the knee extensors and recorded lower motor cortical output in the patients with COPD (4). Taken together, these data support the hypothesis that cerebral processes are involved in COPD muscle weakness.

Mechanisms responsible for brain impairment in COPD: an incomplete view

Although evidence of a major brain impairment in COPD has steadily accumulated since the first study by Fix et al. (36), the trigger for these cerebral alterations remains unknown (37). A model including vascular disease, inflammation, smoking and hypoxia was proposed to explain COPD neuronal damage and dysfunction (25), yet Dodd et al. (2) reported the persistence of neuronal damage and cognitive dysfunction in COPD even after controlling for smoking and stroke risks. Another study found higher cognitive dysfunction in O₂-dependent patients with COPD than in non-dependent patients, with comparable level of systemic inflammation in the two groups (29). This indicates that chronic inflammation, although probably implicated (38), is not the main mechanism of the brain impairment. It also raises doubt about the effectiveness of long-term O₂ supplementation in preventing or correcting cerebral alterations, perhaps because hypoxemia per se is not fully responsible for COPD brain impairment. Indeed, while most studies have blamed chronic hypoxemia and hypercapnia (6, 28), neither direct evidence nor explanatory mechanisms could be clearly provided. Moreover, several studies have reported brain impairment and cognitive dysfunction in non-hypoxemic patients with COPD, raising further doubt about the credibility of this hypothesis (2, 7, 8). Although the evidence that hypoxia in vitro induces cellular necrosis is indisputable, it has long been established that hypoxia exposure alone is not able to induce neuronal damage in vivo. Indeed, a fall in arterial oxygen tension (PaO₂) without ischemia or a drop in blood pressure (which may cause ischemia) does not induce neuronal death/necrosis (39-41). In this sense, it appears that abnormal perfusion is an essential condition for neuronal damage in vivo. The exact mechanisms are examined in detail below.

Brain protection against hypoxemia during wakefulness: mechanisms and differences between patients with COPD and healthy individuals

Cerebral autoregulation is the physiological mechanism that maintains constant cerebral perfusion despite blood pressure changes within the normal range (42). However, during changes in arterial blood gases, cerebral autoregulation mechanisms adjust cerebral blood flow (CBF) through CBF velocity and regulate artery caliber to ensure adequate blood gas delivery to the brain (43). When PaO_2 decreases, CBF increases, and when arterial carbon dioxide tension (PaCO_2) increases, CBF increases. These responses are called cerebrovascular O_2 reactivity and cerebrovascular CO_2 reactivity, respectively. This close coupling between CBF and arterial blood gases was first described by Kety et al. (44). When PaO_2 is decreased in isocapnic conditions, the increase in global and regional CBF can reach up to 200% (9-11). It is assumed that the adaptation of CBF during acute hypoxic exposure is protective, maintaining the stable cerebral oxygen delivery that is a prerequisite for normal brain function (9, 45-47). In contrast, it has been suggested that the increase in CBF in response to a PaCO_2 increase causes CO_2 washout from brain tissue in order to attenuate the level of central CO_2 (10), thereby preventing the deleterious effects of excessive PaCO_2 levels on brain tissue (48, 49). However, it is noteworthy that the deleterious effects were reported for PaCO_2 levels above 100 mmHg (49), values rarely reached in humans.

Effects of hypoxic exposure on CBF in healthy individuals

Isocapnia during acute hypoxic exposure is a very rare phenomenon in healthy humans. Acute hypoxemia normally induces an increase in ventilation, which in turn leads to hypocapnia to improve blood oxygenation (47, 50, 51). This occurrence of hypocapnia during hypoxic exposure subsequently hampers the increase of CBF velocity caused by lower PaO_2 , as hypoxemia and hypocapnia have opposite effects on CBF (52, 53). In addition, as CBF is more sensitive to changes in PaCO_2 than in PaO_2 , this heightens the risk of inadequate oxygen delivery to the brain during acute hypoxemia-hypocapnia (53). Nevertheless, more recent

studies have shown that the modest increase in CBF velocity during acute hypoxemia-hypocapnia is compensated by a greater increase in the caliber of cerebral arteries to ensure normal oxygen delivery to the brain (46, 50).

During chronic hypoxia in healthy humans, cerebral oxygen delivery also remains preserved compared to sea-level values (47, 50, 54, 55). The mechanisms suggest that the adaptations differ from those that occur during acute hypoxic exposure, since a progressive return of CBF toward sea-level values has been observed after several days of hypoxic exposure (54-56). This fall in CBF is nevertheless compensated by an increase in arterial oxygen content, mainly due to respiratory acclimatization and a slight rise in hemoglobin concentration (55), resulting in adequate cerebral oxygen delivery (47, 50, 54, 55). Thus, taken together, the aforementioned findings do not support the occurrence of cerebral hypoxia under either acute or chronic hypoxic exposure.

Effects of hypoxemia on CBF in patients with COPD

Patients with COPD can experience acute hypoxemia (e.g., during exercise-induced oxygen desaturation) and the most severe patients may even experience chronic hypoxemia. In patients with COPD acute and chronic hypoxemia are generally accompanied by normocapnia or hypercapnia, rather than hypocapnia compared to healthy individuals. This is due to ventilation-perfusion mismatch and impaired ventilatory muscle function (57). The combination of hypoxemia and hypercapnia increases CBF much more than hypoxemia or hypercapnia alone, since these two phenomena have cumulative vasodilator effects (56). It is thus possible to speculate that the COPD brain is normally much more protected from cerebral hypoxia than the healthy human brain, on condition that both acute and chronic cerebrovascular reactivity are preserved in COPD. Many studies have provided evidence of cerebrovascular CO₂ reactivity in COPD (58-62), although this response seems mitigated

150 compared with that in healthy controls (59, 60). Regarding acute cerebrovascular O₂
151 reactivity, one study reported a similar CBF increase in patients with COPD and healthy
152 controls in response to arterial oxygen saturation (SaO₂) changes, supporting a preserved
153 response (58). In addition, another study reported higher CBF velocity and an increase in
154 cerebral artery diameter in recently exacerbated patients with COPD (63). More recently,
155 comparable levels of cerebral oxygen delivery during exercise-induced oxygen desaturation
156 were reported when the patients breathed room air and when they breathed oxygen to prevent
157 desaturation (64). This confirms the brain protection against acute hypoxemia in COPD.

158 Regarding the effect of chronic hypoxemia on CBF, a study reported higher CBF velocity and
159 larger cerebral artery diameter using transcranial Doppler in chronic hypoxemic patients with
160 COPD compared with healthy controls (65). This study showed that the mechanisms of
161 cerebral vasodilation persist in patients with COPD during chronic blood gas changes. In
162 addition, the highest CBF levels were found in the hypoxemic-hypercapnic patients,
163 indicating a possible cumulative effect of chronic hypoxemia-hypercapnia on the
164 cerebrovascular vasodilative response (65). Nevertheless, this response is sometimes difficult
165 to observe because of confounding factors (66, 67). For example, CBF is closely coupled with
166 cerebral metabolism: the lower the cerebral metabolism, the lower the CBF is. As patients
167 with COPD exhibit lower resting cerebral metabolism (21, 68, 69), the resting CBF can be
168 lowered in both hypoxemic (66, 67) and non-hypoxemic (62) patients.

169 To conclude, acute and chronic cerebrovascular O₂ reactivity is preserved in COPD,
170 indicating that cerebral oxygen delivery is adequate during hypoxemia in patients with COPD
171 (64). Hence, hypoxemia per se does not induce cerebral hypoxia in COPD and this may
172 explain why the involvement of hypoxemia in triggering neuronal damage in COPD has never
173 been demonstrated.

Cerebrovascular reactivity during sleep compromises brain integrity in chronic respiratory disorders

As the studies cited above have shown, changes in diurnal blood gases are well tolerated by the brain through CBF adaptations. However, this mechanism may be hampered during sleep. Contrary to the adaptations that occur in the waking state, the oxygen desaturation during non-rapid eye movement (NREM) sleep is not accompanied by an increase in CBF (Figure 2). Meadows et al. (13) reduced SaO₂ from five to ten percent during slow-wave sleep in humans and found an unexpected decrease in CBF during hypoxemia. This decoupling of CBF and PaO₂ has also been reported in patients with obstructive sleep apnea (OSA) (12, 70, 71). While decreasing PaO₂ by voluntary breath-holding increases CBF during the waking state (72, 73), CBF tends to decrease during NREM sleep when PaO₂ is decreased by sleep apnea, increasing the risk of inadequate cerebral O₂ delivery (70).

The absence of cerebrovascular O₂ reactivity during NREM sleep makes it more difficult to prevent cerebral hypoxia in patients with cardiorespiratory disorders who experience oxygen desaturation during NREM sleep. Cerebral hypoxia has been reported during sleep in patients with OSA (15, 16). It should be noted that this response seems very specific to the NREM sleep stages, as cerebrovascular reactivity is not impaired during rapid eye movement (REM) sleep (12).

In summary, cerebrovascular reactivity is impaired and even abolished during NREM sleep in humans (13). In patients who experience hypoxemia or desaturation during NREM sleep, cerebral hypoxia can occur and may induce neuronal damage (14). We thus propose that nocturnal desaturation during NREM sleep can act as a trigger for neuronal damage and cerebral dysfunction in patients with COPD (Figure 1).

Desaturation during NREM sleep in COPD: does it exist and, if so, does it matter?

Patients with COPD who are hypoxemic in the waking state usually become more hypoxemic during sleep (74), but nocturnal desaturation can also occur in patients with COPD who are normoxic while awake (17). The prevalence of patients with COPD who are normoxic while awake and who spend at least 30% of the total sleep time (TST) with a mean pulsed oxygen saturation (SpO₂) below 90% ranges from 38 to 70% (17-19). Based on the same criteria, it is also notable that nocturnal desaturation in COPD is observed in approximately half of the patients undergoing long-term oxygen therapy because the diurnal flow rate is often insufficient to prevent nocturnal desaturation (75). However, it is quite difficult to determine the percentage of patients with COPD who desaturate during the NREM sleep stages because all the studies to date have considered the total sleep time, thus including REM sleep. Indeed, as the deepest desaturations occur during REM sleep, this sleep stage has logically been taken as the main marker of COPD sleep abnormalities (74, 76, 77). Nevertheless, it is reasonable to assume that desaturation during NREM sleep occurs in patients with nocturnal desaturation in COPD, even though this has never been specifically assessed. The usual criterion to diagnose sleep desaturation is oxygen desaturation for at least 30% of the total sleep time. As REM sleep represents only approximately 13% of the total sleep time in COPD (78), more than half of the desaturation time is likely to occur during NREM sleep in patients with COPD and significant sleep desaturation.

Future studies to test the hypothesis

The abolition of cerebrovascular O₂ reactivity during NREM sleep was demonstrated in humans (13) and then specifically in patients who experience nocturnal desaturation (11). Transcranial Doppler (58) or near-infrared spectroscopy (64) could be used to assess the extent to which CBF decreases during NREM sleep desaturation in patients with COPD.

Moreover, a follow-up study with correction of NREM sleep desaturation in the desaturating patients, for example by oxygen therapy, would be of great interest. A few studies assessed the effects of oxygen therapy on cognitive function in COPD but the results were inconclusive (79-82). In these studies, the oxygen flow rate was not adapted to the specific needs during sleep which are often higher than during the waking state (75). Therefore, manually or automated oxygen flow titration should be considered to accurately adjust oxygen delivery during NREM sleep (83). Beyond hypothesis testing, the demonstration that preventing NREM sleep desaturation improves cerebral function (or at least stops the decline in function) would constitute a first step in developing new treatments for the neuronal damage and dysfunction of COPD.

Conclusion

In summary, cerebrovascular reactivity to blood gas changes is a mechanism that prevents brain hypoxia in awake humans. During NREM sleep, however, this reactivity is reduced or even totally abolished. Consequently, any oxygen desaturation during this sleep stage will favor neuronal damage. As abnormal blood oxygenation during NREM sleep is a common feature in COPD and a decreased oxygen supply might not be compensated by an increase in cerebral blood flow, the patient's brain is potentially exposed to hypoxic stress. The hypothesis developed above considers NREM sleep desaturation as a potential trigger for neuronal damage and dysfunction in COPD.

Acknowledgment

The authors wish to thank Dr Emilie Tremey for helpful discussions about the manuscript.

Conflict of interest statement

No conflict of interest, financial or otherwise, is declared by the authors.

Funding

No funding was received for this study.

References

- [1] Barnes PJ , Celli BR. Systemic manifestations and comorbidities of COPD, *Eur Respir J.* (2009); **33**: 1165-1185.
- [2] Dodd JW, Chung AW, van den Broek MD, Barrick TR, Charlton RA , Jones PW. Brain structure and function in chronic obstructive pulmonary disease: a multimodal cranial magnetic resonance imaging study, *Am J Respir Crit Care Med.* (2012); **186**: 240-245.
- [3] Ryu CW, Jahng GH, Choi CW, *et al.* Microstructural change of the brain in chronic obstructive pulmonary disease: a voxel-based investigation by MRI, *Copd.* (2013); **10**: 357-366.
- [4] Alexandre F, Heraud N, Oliver N , Varray A. Cortical Implication in Lower Voluntary Muscle Force Production in Non-Hypoxemic COPD Patients, *PloS one.* (2014); **9**: e100961.
- [5] Orth M, Diekmann C, Suchan B, *et al.* Driving performance in patients with chronic obstructive pulmonary disease, *J Physiol Pharmacol.* (2008); **59 Suppl 6**: 539-547.
- [6] Zheng GQ, Wang Y , Wang XT. Chronic hypoxia-hypercapnia influences cognitive function: a possible new model of cognitive dysfunction in chronic obstructive pulmonary disease, *Med Hypotheses.* (2008); **71**: 111-113.
- [7] Gupta PP, Sood S, Atreja A , Agarwal D. A comparison of cognitive functions in non-hypoxemic chronic obstructive pulmonary disease (COPD) patients and age-matched

healthy volunteers using mini-mental state examination questionnaire and event-related potential, P300 analysis, *Lung India*. (2013); **30**: 5-11.

[8] Liesker JJ, Postma DS, Beukema RJ, *et al*. Cognitive performance in patients with COPD, *Respir Med*. (2004); **98**: 351-356.

[9] Harris AD, Murphy K, Diaz CM, *et al*. Cerebral blood flow response to acute hypoxic hypoxia, *NMR Biomed*. (2013); **26**: 1844-1852.

[10] Poulin MJ , Robbins PA. Influence of cerebral blood flow on the ventilatory response to hypoxia in humans, *Exp Physiol*. (1998); **83**: 95-106.

[11] Shapiro W, Wasserman AJ, Baker JP , Patterson JL, Jr. Cerebrovascular response to acute hypocapnic and eucapnic hypoxia in normal man, *J Clin Invest*. (1970); **49**: 2362-2368.

[12] Hajak G, Klingelhofer J, Schulz-Variszegi M, Sander D , Ruther E. Sleep apnea syndrome and cerebral hemodynamics, *Chest*. (1996); **110**: 670-679.

[13] Meadows GE, O'Driscoll DM, Simonds AK, Morrell MJ , Corfield DR. Cerebral blood flow response to isocapnic hypoxia during slow-wave sleep and wakefulness, *J Appl Physiol*. (2004); **97**: 1343-1348.

[14] Corfield DR , Meadows GE. Control of cerebral blood flow during sleep and the effects of hypoxia, *Adv Exp Med Biol*. (2006); **588**: 65-73.

[15] Matsuo A, Inoue Y, Namba K , Chiba H. Changes in cerebral hemoglobin indices in obstructive sleep apnea syndrome with nasal continuous positive airway pressure treatment, *Sleep Breath*. (2011); **15**: 487-492.

[16] Olopade C, Mensah E, Gupta R, *et al*. Noninvasive determination of brain tissue oxygenation during sleep in obstructive sleep apnea: A near-infrared spectroscopic approach, *Sleep*. (2007); **30**: 1747-1755.

- 298 [17] Lacasse Y, Series F, Vujovic-Zotovic N, *et al.* Evaluating nocturnal oxygen
299 desaturation in COPD--revised, *Respir Med.* (2011); **105**: 1331-1337.
- 300 [18] Levi-Valensi P, Weitzenblum E, Rida Z, *et al.* Sleep-related oxygen desaturation and
301 daytime pulmonary haemodynamics in COPD patients, *Eur Respir J.* (1992); **5**: 301-
302 307.
- 303 [19] Chaouat A, Weitzenblum E, Kessler R, *et al.* Sleep-related O2 desaturation and
304 daytime pulmonary haemodynamics in COPD patients with mild hypoxaemia, *Eur*
305 *Respir J.* (1997); **10**: 1730-1735.
- 306 [20] van Dijk EJ, Vermeer SE, de Groot JC, *et al.* Arterial oxygen saturation, COPD, and
307 cerebral small vessel disease, *J Neurol Neurosurg Psychiatry.* (2004); **75**: 733-736.
- 308 [21] Shim TS, Lee JH, Kim SY, *et al.* Cerebral metabolic abnormalities in COPD patients
309 detected by localized proton magnetic resonance spectroscopy, *Chest.* (2001); **120**:
310 1506-1513.
- 311 [22] Zhang H, Wang X, Lin J, *et al.* Reduced regional gray matter volume in patients with
312 chronic obstructive pulmonary disease: a voxel-based morphometry study, *AJNR Am J*
313 *Neuroradiol.* (2013); **34**: 334-339.
- 314 [23] Li J , Fei GH. The unique alterations of hippocampus and cognitive impairment in
315 chronic obstructive pulmonary disease, *Respiratory research.* (2013); **14**: 140.
- 316 [24] Lahousse L, Vernooij MW, Darweesh SK, *et al.* Chronic obstructive pulmonary
317 disease and cerebral microbleeds. The Rotterdam Study, *Am J Respir Crit Care Med.*
318 (2013); **188**: 783-788.
- 319 [25] Dodd JW, Getov SV , Jones PW. Cognitive function in COPD, *Eur Respir J.* (2010);
320 **35**: 913-922.
- 321 [26] Villeneuve S, Pepin V, Rahayel S, *et al.* Mild Cognitive Impairment in Moderate to
322 Severe Chronic Obstructive Pulmonary Disease: A Preliminary Study, *Chest.* (2012).

- 323 [27] Kirkil G, Tug T, Ozel E, Bulut S, Tekatas A , Muz MH. The evaluation of cognitive
324 functions with P300 test for chronic obstructive pulmonary disease patients in attack
325 and stable period, *Clin Neurol Neurosurg.* (2007); **109**: 553-560.
- 326 [28] Schou L, Ostergaard B, Rasmussen LS, Rydahl-Hansen S , Phanareth K. Cognitive
327 dysfunction in patients with chronic obstructive pulmonary disease--a systematic
328 review, *Respir Med.* (2012); **106**: 1071-1081.
- 329 [29] Borson S, Scanlan J, Friedman S, *et al.* Modeling the impact of COPD on the brain,
330 *International journal of chronic obstructive pulmonary disease.* (2008); **3**: 429-434.
- 331 [30] Salik Y, Ozalevli S , Cimrin AH. Cognitive function and its effects on the quality of
332 life status in the patients with chronic obstructive pulmonary disease (COPD), *Arch*
333 *Gerontol Geriatr.* (2007); **45**: 273-280.
- 334 [31] Singh B, Parsaik AK, Mielke MM, *et al.* Chronic obstructive pulmonary disease and
335 association with mild cognitive impairment: the Mayo Clinic Study of Aging, *Mayo*
336 *Clin Proc.* (2013); **88**: 1222-1230.
- 337 [32] Karakontaki F, Gennimata SA, Palamidas AF, *et al.* Driving-Related
338 Neuropsychological Performance in Stable COPD Patients, *Pulm Med.* (2013); **2013**:
339 297371.
- 340 [33] Mohamed-Hussein AA, Hamed SA , Abdel-Hakim N. Cerebral cortical dysfunction in
341 chronic obstructive pulmonary disease: role of transcranial magnetic stimulation, *Int J*
342 *Tuberc Lung Dis.* (2007); **11**: 515-521.
- 343 [34] Oliviero A, Corbo G, Tonali PA, *et al.* Functional involvement of central nervous
344 system in acute exacerbation of chronic obstructive pulmonary disease A preliminary
345 transcranial magnetic stimulation study, *J Neurol.* (2002); **249**: 1232-1236.

- 346 [35] Vivodtzev I, Flore P, Levy P , Wuyam B. Voluntary activation during knee extensions
347 in severely deconditioned patients with chronic obstructive pulmonary disease: benefit
348 of endurance training, *Muscle Nerve*. (2008); **37**: 27-35.
- 349 [36] Fix AJ, Golden CJ, Daughton D, Kass I , Bell CW. Neuropsychological deficits
350 among patients with chronic obstructive pulmonary disease, *Int J Neurosci*. (1982);
351 **16**: 99-105.
- 352 [37] Rodriguez-Roisin R, Llufrui S , Fabbri LM. Changes in your breathing can change
353 your brain, *Am J Respir Crit Care Med*. (2013); **188**: 763-764.
- 354 [38] Bratek A, Zawada K, Beil-Gawelczyk J, *et al*. Depressiveness, symptoms of anxiety
355 and cognitive dysfunctions in patients with asthma and chronic obstructive pulmonary
356 disease (COPD): possible associations with inflammation markers: a pilot study, *J*
357 *Neural Transm*. (2014).
- 358 [39] de Courten-Myers GM, Yamaguchi S, Wagner KR, Ting P , Myers RE. Brain injury
359 from marked hypoxia in cats: role of hypotension and hyperglycemia, *Stroke*. (1985);
360 **16**: 1016-1021.
- 361 [40] Miyamoto O , Auer RN. Hypoxia, hyperoxia, ischemia, and brain necrosis, *Neurology*.
362 (2000); **54**: 362-371.
- 363 [41] Pearigen P, Gwinn R , Simon R. The effects in vivo of hypoxia on brain injury, *Brain*
364 *Research*. (1996); **725**: 184-191.
- 365 [42] Paulson OB, Strandgaard S , Edvinsson L. Cerebral autoregulation, *Cerebrovasc*
366 *Brain Metab Rev*. (1990); **2**: 161-192.
- 367 [43] Willie CK, Macleod DB, Shaw AD, *et al*. Regional brain blood flow in man during
368 acute changes in arterial blood gases, *J Physiol*. (2012); **590**: 3261-3275.

- 369 [44] Kety SS , Schmidt CF. The Effects of Altered Arterial Tensions of Carbon Dioxide
370 and Oxygen on Cerebral Blood Flow and Cerebral Oxygen Consumption of Normal
371 Young Men, *J Clin Invest.* (1948); **27**: 484-492.
- 372 [45] Binks AP, Cunningham VJ, Adams L , Banzett RB. Gray matter blood flow change is
373 unevenly distributed during moderate isocapnic hypoxia in humans, *J Appl Physiol*
374 (1985). (2008); **104**: 212-217.
- 375 [46] Wilson MH, Edsell ME, Davagnanam I, *et al.* Cerebral artery dilatation maintains
376 cerebral oxygenation at extreme altitude and in acute hypoxia--an ultrasound and MRI
377 study, *J Cereb Blood Flow Metab.* (2011); **31**: 2019-2029.
- 378 [47] Wolff CB. Cerebral blood flow and oxygen delivery at high altitude, *High Alt Med*
379 *Biol.* (2000); **1**: 33-38.
- 380 [48] Vannucci RC, Towfighi J, Brucklacher RM , Vannucci SJ. Effect of extreme
381 hypercapnia on hypoxic-ischemic brain damage in the immature rat, *Pediatr Res.*
382 (2001); **49**: 799-803.
- 383 [49] Zhou Q, Cao B, Niu L, *et al.* Effects of permissive hypercapnia on transient global
384 cerebral ischemia-reperfusion injury in rats, *Anesthesiology.* (2010); **112**: 288-297.
- 385 [50] Imray C, Chan C, Stubbings A, *et al.* Time Course Variations in the Mechanisms by
386 Which Cerebral Oxygen Delivery Is Maintained on Exposure to Hypoxia/Altitude,
387 *High Alt Med Biol.* (2014).
- 388 [51] Richalet JP. Operation Everest III: COMEX '97, *High Alt Med Biol.* (2010); **11**: 121-
389 132.
- 390 [52] Fortune JB, Bock D, Kupinski AM, Stratton HH, Shah DM , Feustel PJ. Human
391 cerebrovascular response to oxygen and carbon dioxide as determined by internal
392 carotid artery duplex scanning, *J Trauma.* (1992); **32**: 618-627; discussion 627-618.

- 393 [53] Norcliffe LJ, Rivera-Ch M, Claydon VE, *et al.* Cerebrovascular responses to hypoxia
394 and hypocapnia in high-altitude dwellers, *J Physiol.* (2005); **566**: 287-294.
- 395 [54] Subudhi AW, Fan JL, Evero O, *et al.* AltitudeOmics: Effect of ascent and
396 acclimatization to 5260 m on regional cerebral oxygen delivery, *Exp Physiol.* (2014).
- 397 [55] Wolff CB, Barry P, Collier DJ. Cardiovascular and respiratory adjustments at altitude
398 sustain cerebral oxygen delivery -- Severinghaus revisited, *Comp Biochem Physiol A*
399 *Mol Integr Physiol.* (2002); **132**: 221-229.
- 400 [56] Brugniaux JV, Hodges AN, Hanly PJ, Poulin MJ. Cerebrovascular responses to
401 altitude, *Respir Physiol Neurobiol.* (2007); **158**: 212-223.
- 402 [57] Rabe KF, Hurd S, Anzueto A, *et al.* Global strategy for the diagnosis, management,
403 and prevention of chronic obstructive pulmonary disease: GOLD executive summary,
404 *Am J Respir Crit Care Med.* (2007); **176**: 532-555.
- 405 [58] Bernardi L, Casucci G, Haider T, *et al.* Autonomic and cerebrovascular abnormalities
406 in mild COPD are worsened by chronic smoking, *Eur Respir J.* (2008); **32**: 1458-
407 1465.
- 408 [59] Clivati A, Ciofetti M, Cavestri R, Longhini E. Cerebral vascular responsiveness in
409 chronic hypercapnia, *Chest.* (1992); **102**: 135-138.
- 410 [60] Hartmann SE, Pialoux V, Leigh R, Poulin MJ. Decreased cerebrovascular response to
411 CO₂ in post-menopausal females with COPD: role of oxidative stress, *Eur Respir J.*
412 (2012); **40**: 1354-1361.
- 413 [61] Sari A, Oshiata S, Toriumi T, *et al.* Cerebral blood flow and cerebral oxygen
414 consumption in patients with COPD on mechanical ventilation, *Intensive Care Med.*
415 (1992); **18**: 455-458.

- 416 [62] Van de Ven MJ, Colier WN, Van der Sluijs MC, Kersten BT, Oeseburg B , Folgering
417 H. Ventilatory and cerebrovascular responses in normocapnic and hypercapnic COPD
418 patients, *Eur Respir J.* (2001); **18**: 61-68.
- 419 [63] Yildiz S, Kaya I, Cece H, *et al.* Impact of COPD exacerbation on cerebral blood flow,
420 *Clin Imaging.* (2012); **36**: 185-190.
- 421 [64] Vogiatzis I, Louvaris Z, Habazettl H, *et al.* Cerebral cortex oxygen delivery and
422 exercise limitation in patients with COPD, *Eur Respir J.* (2013); **41**: 295-301.
- 423 [65] Albayrak R, Fidan F, Unlu M, *et al.* Extracranial carotid Doppler ultrasound
424 evaluation of cerebral blood flow volume in COPD patients, *Respir Med.* (2006); **100**:
425 1826-1833.
- 426 [66] Antonelli Incalzi R, Marra C, Giordano A, *et al.* Cognitive impairment in chronic
427 obstructive pulmonary disease--a neuropsychological and spect study, *J Neurol.*
428 (2003); **250**: 325-332.
- 429 [67] Ortapamuk H , Naldoken S. Brain perfusion abnormalities in chronic obstructive
430 pulmonary disease: comparison with cognitive impairment, *Ann Nucl Med.* (2006); **20**:
431 99-106.
- 432 [68] Karakas E, Yildizhan M, Karakas O, *et al.* Examining cerebral metabolic
433 abnormalities in chronic obstructive pulmonary disease (COPD) patients by localized
434 proton magnetic resonance spectroscopy (MRS), *Clin Ter.* (2013); **164**: e179-182.
- 435 [69] Sinha S, Kumar V, Jagannathan NR , Pandey RM. Proton magnetic resonance
436 spectroscopy of brain to study the cerebral metabolic abnormalities in COPD patients:
437 a case control study in north India, *Indian J Chest Dis Allied Sci.* (2009); **51**: 15-19.
- 438 [70] Balfors EM , Franklin KA. Impairment of cerebral perfusion during obstructive sleep
439 apneas, *Am J Respir Crit Care Med.* (1994); **150**: 1587-1591.

- 440 [71] Meyer JS, Ishikawa Y, Hata T , Karacan I. Cerebral blood flow in normal and
441 abnormal sleep and dreaming, *Brain Cogn.* (1987); **6**: 266-294.
- 442 [72] Cross TJ, Kavanagh JJ, Breskovic T, Johnson BD , Dujic Z. Dynamic Cerebral
443 Autoregulation Is Acutely Impaired during Maximal Apnoea in Trained Divers, *PloS*
444 *one.* (2014); **9**: e87598.
- 445 [73] Palada I, Obad A, Bakovic D, Valic Z, Ivancev V , Dujic Z. Cerebral and peripheral
446 hemodynamics and oxygenation during maximal dry breath-holds, *Respir Physiol*
447 *Neurobiol.* (2007); **157**: 374-381.
- 448 [74] Weitzenblum E , Chaouat A. Sleep and chronic obstructive pulmonary disease, *Sleep*
449 *Med Rev.* (2004); **8**: 281-294.
- 450 [75] Plywaczewski R, Sliwinski P, Nowinski A, Kaminski D , Zielinski J. Incidence of
451 nocturnal desaturation while breathing oxygen in COPD patients undergoing long-
452 term oxygen therapy, *Chest.* (2000); **117**: 679-683.
- 453 [76] Collop N. Sleep and sleep disorders in chronic obstructive pulmonary disease,
454 *Respiration; international review of thoracic diseases.* (2010); **80**: 78-86.
- 455 [77] McNicholas WT, Verbraecken J , Marin JM. Sleep disorders in COPD: the forgotten
456 dimension, *Eur Respir Rev.* (2013); **22**: 365-375.
- 457 [78] McSharry DG, Ryan S, Calverley P, Edwards JC , McNicholas WT. Sleep quality in
458 chronic obstructive pulmonary disease, *Respirology.* (2012); **17**: 1119-1124.
- 459 [79] Thakur N, Blanc PD, Julian LJ, *et al.* COPD and cognitive impairment: the role of
460 hypoxemia and oxygen therapy, *International journal of chronic obstructive*
461 *pulmonary disease.* (2010); **5**: 263-269.
- 462 [80] Heaton RK, Grant I, McSweeney AJ, Adams KM , Petty TL. Psychologic effects of
463 continuous and nocturnal oxygen therapy in hypoxemic chronic obstructive
464 pulmonary disease, *Arch Intern Med.* (1983); **143**: 1941-1947.

- 465 [81] Incalzi RA, Chiappini F, Fuso L, Torrice MP, Gemma A , Pistelli R. Predicting
466 cognitive decline in patients with hypoxaemic COPD, *Respir Med.* (1998); **92**: 527-
467 533.
- 468 [82] Incalzi RA, Gemma A, Marra C, Muzzolon R, Capparella O , Carbonin P. Chronic
469 obstructive pulmonary disease. An original model of cognitive decline, *Am Rev Respir*
470 *Dis.* (1993); **148**: 418-424.
- 471 [83] Lellouche F, Lipes J , L'Her E. Optimal oxygen titration in patients with chronic
472 obstructive pulmonary disease: a role for automated oxygen delivery?, *Can Respir J.*
473 (2013); **20**: 259-261.

Figures

Figure 1: Hypoxemia during non-rapid eye movement (NREM) sleep promotes brain hypoxia and potentially damages brain tissue

Figure 2: Mean flow velocity (MFV) in the right medial cerebral artery in healthy controls and patients with obstructive sleep apnea during wakefulness and sleep during which hypoxemia occurred: non-rapid eye movement sleep (NREM; stage 2) and rapid eye movement sleep (REM) of the second sleep cycle [Adapted from the data of Hajak et al. (12)]. Apnea-induced hypoxemia is compensated during REM sleep by an MFV increase, but this adjustment is totally abolished during NREM sleep, where MFV tends to decrease, mimicking the healthy controls' MFV kinetics. * $p < 0.05$ between groups.